the use of emollients and topical corticosteroids of appropriate potency to treat aIected sites
topical calcineurin inhibitors (including tacrolimus and pimecrolimus)
licensed for use in adults and children two years of age and older as second-line treatments for moderate to severe eczema that has not been controlled by topical corticosteroids, when there is serious risk of important adverse eIects from further topical corticosteroid use (particularly irreversible skin atrophy)
systemic immunosuppressive treatments are reserved for the treatment of more severe cases of eczema that have been inadequately controlled with topical treatments (such as topical corticosteroids and topical calcineurin inhibitors)
Reference:
Sawangjit R et al. Systemic treatments for eczema: a network meta-analysis. Cochrane Database of Systematic Reviews 2020, Issue 9. Art. No.: CD013206. DOI:10.1002/14651858.CD013206.pub2
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.